24 May 2024

Scancell Holdings plc

("Scancell" or the "Company")

Scancell to present at the 2024 ASCO Annual Meeting

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, is pleased to announce that it will be presenting during a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 31 May to 4 June 2024, in Chicago, Illinois.

Scancell will be presenting a poster highlighting data from its open-label Phase 2 SCOPE trial, investigating its cancer vaccine, SCIB1, in combination with checkpoint inhibitors (CPIs) in advanced melanoma. Exceptional results from the first 13 patients receiving SCIB1 have already been demonstrated, with an objective response rate of 85%.

Professor Lindy Durrant, Chief Executive Officer of Scancell, said: "ASCO is one the leading events for companies working in the field of oncology and so we were very proud to be selected to present a poster at this year's conference.  Our ongoing Phase 2 SCOPE trial of our melanoma cancer vaccine, SCIB1, has shown highly promising efficacy and safety data so far and we are hugely excited to highlight the progress Scancell is making in the cancer vaccine space."

Poster presentation details

Title: A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.

Session type and title: Poster Session - Melanoma/Skin Cancers

Session date and time: 1 June 2024, 1:30 PM - 4:30 PM CDT

If you would like to arrange a meeting at the conference, please contact [email protected].

-ENDS-

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/